Trials / Unknown
UnknownNCT04658277
Effect of Long Term Clarithromycin for Prevention of Exacerbations in Non-cystic Fibrosis Bronchiectasis in Asian Populations
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Chinese University of Hong Kong · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
clarithromycin may reduce the exacerbations in middle-aged and elderly patients with non-CF bronchiectasis. The study is aimed to (A) investigate the etiologies and clinical features of patients with bronchiectasis, (B) compare the effect of clarithromycin 250mg daily on the frequency of exacerbations, quality of life and lung function, stratified according to the degree of bronchiectasis severity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Clarithromycin | Patients in the intervention arm will take Clarithromycin 250mg daily. |
| OTHER | Usual care | Patients will receive usual medical care |
Timeline
- Start date
- 2020-10-01
- Primary completion
- 2023-09-30
- Completion
- 2023-09-30
- First posted
- 2020-12-08
- Last updated
- 2021-10-29
Locations
1 site across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT04658277. Inclusion in this directory is not an endorsement.